Brought to you by 
Verus Pharmaceuticals grosses $78mm with first venture round
30 Jun 2005
Executive Summary
Pediatric specialty drug company Verus Pharmaceuticals has raised $78mm with its Series A venture round of preferred shares led by Domain Associates and Prospect Venture Partners. Other backers included the Paul Royalty Fund (managed by Paul Capital Partners), MPM Capital, Montreux Equity Partners, Athenian Venture Partners, Windamere, and private investors. Paul Royalty provided an additional $20mm in exchange for royalties on at least one undisclosed product.
Deal Industry
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Verus Pharmaceuticals grosses $78mm with first venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice